AG真人官方

Savara Inc. reported widening losses as it advances its sole product candidate, MOLBREEVI, an inhaled GM-CSF for autoimmune pulmonary alveolar proteinosis. Net loss was $30.4 million for the quarter and $57.0 million for the six months, up from $22.2 million and $42.6 million a year earlier, driven by higher research-and-development and commercial-preparation costs.

The company holds $17.4 million in cash and $129.0 million in short-term investments (total ~$146.4 million) and states this is sufficient to fund operations for at least the next 12 months. Savara received an FDA Refusal to File for its BLA but says the RTF raised CMC information requests only, not safety or efficacy; the company plans a December resubmission and will request Priority Review. Savara has a $200 million Hercules term loan facility with an initial $30 million draw, conditional future tranches tied to regulatory and revenue milestones and covenanted cash requirements that could restrict liquidity.

Schedule 13G filing for Savara Inc. (SVRA) shows that a group of Venrock Healthcare Capital Partners funds and related managers/individuals has crossed the 5% disclosure threshold.

• Reporting group: Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, and principals Nimish Shah and Bong Y. Koh.
• Aggregate beneficial ownership: 9,021,507 common shares.
• Ownership breakdown: 1,997,410 shares (VHCP III); 199,772 shares (VHCP Co-Investment III); 6,824,325 shares (VHCP EG).
• Percentage of class: 5.2% of Savara鈥檚 172,836,922 outstanding shares (as of 13 May 2025).
• Voting & dispositive power: 0 shares sole; 9,021,507 shares shared鈥攊ndicating coordinated but passive ownership. Filing is under Rule 13d-1(c), not 13D, so the group states no intent to influence control.
• Date of event triggering filing: 30 June 2025; filing signed 08 July 2025.

The disclosure signals that Venrock, a life-science鈥揻ocused investor, holds a meaningful but non-controlling position in Savara. Investors often view recognized sector specialists taking a >5% stake as a vote of confidence, yet the filing itself does not imply any change in Savara鈥檚 strategy, capital structure, or governance. The stake is passive and therefore has limited immediate operational impact.

Director Richard Hawkins of Savara Inc (SVRA) reported a significant insider purchase of 48,225 shares of Common Stock on June 20, 2025, at a weighted average price of $2.044 per share, with prices ranging from $2.0345 to $2.045. The transaction increased Hawkins' direct ownership to 115,466 shares. This Form 4 filing, submitted on June 23, 2025, represents a notable insider buying activity, with the director investing approximately $98,572 in the company's stock. The purchase demonstrates confidence in the company's prospects from a key insider, as Hawkins serves on Savara's Board of Directors. The transaction was executed through multiple trades within a narrow price range.